Stock Market Today: Stocks Soar on Apple Buyback News, Jobs Data
The main indexes rallied hard to end the week thanks to Apple's $110 billion stock repurchase plan and a big April payrolls miss.
![Apple logo seen on storefront](https://cdn.mos.cms.futurecdn.net/6M4pbPZQNDHzTJu9QNVaSF-415-80.jpg)
Stocks jumped out of the gate Friday and never looked back. Sentiment got a major lift thanks to a positive reaction to Apple's (AAPL) quarterly earnings report and a bad-news-is-good-news jobs report.
The excitement got started late Thursday when Apple reported higher-than-expected earnings and revenue for its fiscal second quarter. The iPhone maker also unveiled a record $110 billion stock buyback program and its 12th straight annual dividend hike.
"We believe these results appear to change the narrative on the AAPL story, as China is holding up better than expected and there are a host of upcoming events and catalysts on the horizon that could improve investor sentiment and drive consensus estimates higher," says CFRA Research analyst Angelo Zino, who maintained a Buy rating on Apple after earnings.
![https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-200-80.png](https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-320-80.png)
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
One of those events occurs next Tuesday, May 7, when Apple is expected to unveil new iPads for the first time in two years.
Amgen rallies after earnings, weight-loss drug news
Apple stock surged 6.0% after earnings, but it was far from the best Dow Jones stock today. Rather, that title went to Amgen (AMGN), which spiked 11.8% after its earnings report.
The drugmaker reported earnings of $3.96 per share on $7.45 billion in revenue, more than analysts expected. More notable was news Amgen is discontinuing the development of its weight-loss pill and instead preparing for a Phase III study of its obesity injectable, MariTide. Amgen executives said Phase II data for the weight-loss drug is encouraging and will be released later this year.
"While we appreciate there is still plenty of work ahead (full Phase II data, starting Phase III, etc.), the reality is AMGN probably has a 'monthly' drug on their hands and can be a $5 billion to $10 billion-plus player in the future," says Jefferies analyst Michael Yee (Buy). "This should drive a re-rating of the stock as it remains very under-owned across the Street."
Jobs report shows wage growth cools
On the economic front, investors were busy dissecting the April jobs report. Data from the Bureau of Labor Statistics showed the U.S. added 175,000 new jobs in April, the smallest increase in six months. The unemployment rate edged up to 3.9% from 3.8% and average hourly earnings – a measure of inflation – rose 3.9% year-over-year vs March's 4.1% increase.
"In an environment where the market is worried about inflation, a softer jobs report with (slightly) higher unemployment, lower-than-expected wage growth and job creation shows that inflation pressure from wages is easing," says Chris Zaccarelli, chief investment officer for Independent Advisor Alliance.
Following Federal Reserve Chair Jerome Powell's press conference this week where he indicated more rate hikes were unlikely, "the market is back to risk-on mode as long as the Fed maintains an easing bias," Zaccarelli adds.
Indeed, at the close, the Dow Jones Industrial Average was up 1.2% at 38,675, the S&P 500 was 1.3% higher at 5,127, and the Nasdaq Composite had gained 2.0% to 16,156.
Related content
To continue reading this article
please register for free
This is different from signing in to your print subscription
Why am I seeing this? Find out more here
With over a decade of experience writing about the stock market, Karee Venema is the senior investing editor at Kiplinger.com. She joined the publication in April 2021 after 10 years of working as an investing writer and columnist at Schaeffer's Investment Research. In her previous role, Karee focused primarily on options trading, as well as technical, fundamental and sentiment analysis.
-
Stock Market Today: Stocks Give Up Gains Even as Inflation Ebbs
The main indexes closed lower Friday but ended the first half with impressive gains.
By Karee Venema Published
-
Best Places to Rent 2024 — How Does Your City Rank?
The best places to rent in the U.S. include Miami, suburban Chicago and North Jersey, according to a new survey from RentCafe.
By Kathryn Pomroy Published
-
Stock Market Today: Stocks Give Up Gains Even as Inflation Ebbs
The main indexes closed lower Friday but ended the first half with impressive gains.
By Karee Venema Published
-
Nokia to Acquire Infinera in $2.3 Billion Deal: What to Know
Nokia will acquire Infinera as it looks to expand its optical-networking presence. Here's what you need to know.
By Joey Solitro Published
-
Trump Media & Technology Stock Stays Volatile After Debate
Trump Media & Technology stock has traded erratically in recent months and last night's presidential debate sparked more volatility in DJT shares.
By Joey Solitro Published
-
Nike Stock Sinks on Dismal Sales Forecast: What to Know
Nike stock is spiraling Friday after the athletic and apparel retailer missed sales estimates for its most recent quarter and lowered its outlook for its new fiscal year.
By Joey Solitro Published
-
Stock Market Today: Stocks End Higher Ahead of May PCE Data
Micron Technology, Walgreens Boots Alliance and Levi's were three of Thursday's biggest movers.
By Karee Venema Published
-
How to Find the Best Small-Cap Stocks to Buy
Wall Street's best small-cap stocks to buy include biotech, real estate and industrials names.
By Dan Burrows Published
-
Levi Strauss Stock Spirals on Revenue Miss: What to Know
Levi Strauss stock is lower Thursday after the denim company's top line missed estimates amid a "cautious" consumer environment.
By Joey Solitro Published
-
Walgreens Stock Hits 27-Year Low After Massive Earnings Miss
Walgreens Boots Alliance stock is tanking Thursday the pharmacy retailer came up short of earnings expectations and slashed its full-year outlook. Here's what you need to know.
By Joey Solitro Published